Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coya Therapeutics, Inc. (COYA : NSDQ)

• Company Description    Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $4.71 Daily Weekly Monthly 20 Day Moving Average: 185,554 shares Shares Outstanding: 20.92 (millions) Market Capitalization: $98.55 (millions) Beta: 0.27 52 Week High: $8.29 52 Week Low: $3.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.05% 11.72% 12 Week -21.24% -23.92% Year To Date -18.79% -18.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5850 San Felipe St Suite 500 - HOUSTON,TX 77057 USA ph: 800-587-8170 fax: - ir@coyatherapeutics.com http://www.coyatherapeutics.com

• General Corporate Information    Officers Arun Swaminathan - Chief Executive Officer and Director Howard Berman - Executive Chairman David Snyder - Chief Operating Officer;Chief Financial Officer Ann Lee - Director Anabella Villalobos - Director Peer Information Coya Therapeutics, Inc. (CORR.) Coya Therapeutics, Inc. (RSPI) Coya Therapeutics, Inc. (CGXP) Coya Therapeutics, Inc. (BGEN) Coya Therapeutics, Inc. (GTBP) Coya Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 22407B108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 20.92 Most Recent Split Date: (:1) Beta: 0.27 Market Capitalization: $98.55 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.89 Price/Cash Flow: - Price / Sales: 24.71 EPS Growth vs. Year Ago Period: 61.54% vs. Previous Quarter: 72.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 2,073.17% ROE 12/31/25 - - 09/30/25 - -55.76 06/30/25 - -61.05 ROA 12/31/25 - - 09/30/25 - -48.35 06/30/25 - -53.61 Current Ratio 12/31/25 - - 09/30/25 - 8.73 06/30/25 - 7.43 Quick Ratio 12/31/25 - - 09/30/25 - 8.73 06/30/25 - 7.43 Operating Margin 12/31/25 - - 09/30/25 - -449.30 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - -462.24 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -480.29 06/30/25 - -4,966.75 Book Value 12/31/25 - - 09/30/25 - 1.63 06/30/25 - 1.69 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©